Bausch Health Cos Inc. $BHC Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its position in shares of Bausch Health Cos Inc. (NYSE:BHC) by 12.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 10,679,760 shares of the company’s stock after selling 1,561,312 shares during the quarter. Vanguard Group Inc.’s holdings in Bausch Health Cos were worth $74,150,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Tidal Investments LLC lifted its holdings in shares of Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after buying an additional 1,276 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in Bausch Health Cos by 2.5% during the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock worth $690,000 after acquiring an additional 2,552 shares during the period. Russell Investments Group Ltd. grew its holdings in Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares during the period. Bfsg LLC grew its holdings in Bausch Health Cos by 32.8% during the third quarter. Bfsg LLC now owns 14,465 shares of the company’s stock worth $93,000 after acquiring an additional 3,570 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares during the period. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on BHC shares. Barclays dropped their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Royal Bank Of Canada dropped their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Finally, Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $8.00.

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock opened at $5.46 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. Bausch Health Cos Inc. has a twelve month low of $4.41 and a twelve month high of $8.69. The business has a 50-day moving average price of $5.43 and a 200 day moving average price of $6.16. The firm has a market cap of $2.04 billion, a PE ratio of -1.68 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion. Sell-side analysts predict that Bausch Health Cos Inc. will post 4.08 earnings per share for the current fiscal year.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.